Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 May 22;171(2):325–334. doi: 10.1007/s10549-018-4828-5

Table 1.

Characteristics of Patients Treated with Bevacizumab Plus Letrozole

Characteristic Patients Treated with
Bevacizumab Plus Letrozole
(n=112)
Median Age – year (range) 56 (25–85)
Age- no. (%) <65
≥65		 87 (77.7%)
25 (22.3%)
Race- no. (%) White
Other
Unknown		 103 (92.0%)
6 (5.4%)
3 (2.7%)
Ethnicity- no. (%) Hispanic or Latino
Not Hispanic or Latino
Unknown/Not reported		 1 (0.9%)
92 (82.1%)
19 (17.0%)
Karnofsky Performance Status- no.
(%)		 100
90
80
70		 63 (56.3%)
35 (31.3%)
10 (8.9%)
4 (3.6%)
Hormone Receptor Status- no. (%) ER+
PR+
HER2+		 112 (100.0%)
89 (79.5%)
2 (1.8%)